SNGX

Soligenix Inc

Oct 17 • 02:26PM ET

1.55

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: TGTX MDGL AKBA BCRX TNXP AVIR KPTI APT ONCT FENC

Index	-	P/E	-	EPS (ttm)	-3.85	Insider Own	0.63%	Shs Outstand	9.86M	Perf Week	-7.74%
Market Cap	15.28M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	32.20%	Shs Float	9.80M	Perf Month	-43.84%
Enterprise Value	10.59M	PEG	-	EPS next Q	-0.56	Inst Own	1.92%	Short Float	1.25%	Perf Quarter	11.51%
Income	-10.65M	P/S	-	EPS this Y	57.38%	Inst Trans	0.57%	Short Ratio	0.01	Perf Half Y	-26.19%
Sales	0.00M	P/B	2.97	EPS next Y	50.00%	ROA	-136.26%	Short Interest	0.12M	Perf YTD	-42.49%
Book/sh	0.52	P/C	3.00	EPS next 5Y	42.66%	ROE	-402.19%	52W High	6.23 -75.12%	Perf Year	-56.94%
Cash/sh	0.52	P/FCF	-	EPS past 3/5Y	59.52% 46.71%	ROIC	-499.43%	52W Low	1.09 42.20%	Perf 3Y	-98.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.72% 11.48%	Perf 5Y	-99.64%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	59.81%	Oper. Margin	-	ATR (14)	0.22	Perf 10Y	-99.94%
Dividend Ex-Date	-	Quick Ratio	1.46	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	39.50	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.46	EPS Q/Q	36.91%	SMA20	-1.34%	Beta	1.91	Target Price	10.00
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	-36.29%	Rel Volume	0.03	Prev Close	1.55
Employees	16	LT Debt/Eq	0.16	Earnings	Aug 14 BMO	SMA200	-28.52%	Avg Volume	10.86M	Price	1.55
IPO	Apr 04, 1994	Option/Short	No / Yes	EPS/Sales Surpr.	10.87% -	Trades		Volume	215,570	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-20	Downgrade	Dawson James	Buy → Neutral
Jan-31-18	Downgrade	H.C. Wainwright	Buy → Neutral	$5.50 → $2.70
Aug-14-17	Reiterated	Maxim Group	Buy	$4 → $5
Jul-17-17	Initiated	H.C. Wainwright	Buy	$11

Oct-14-25 07:30AM	Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire) -5.23%
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile) +10.37%
Oct-07-25 07:30AM	Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) +19.71%
Sep-30-25 07:30AM	Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire)
Sep-29-25 04:05PM	Soligenix Announces Closing of $7.5 Million Public Offering (PR Newswire) -7.50%
06:33AM	Loading…
Sep-26-25 06:33AM	Soligenix Announces Pricing of $7.5 Million Public Offering (PR Newswire) -25.93%
Sep-23-25 07:30AM	Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor (PR Newswire) -16.31%
Sep-04-25 07:30AM	Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses (PR Newswire)
Sep-02-25 07:30AM	Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +78.42%
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results (PR Newswire)
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behcet's Disease after Reviewing Recent Phase 2 Clinical Study Results (PR Newswire)
Aug-14-25 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results (PR Newswire) +20.00%
Aug-08-25 08:30AM	NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer (GlobeNewswire) -11.85%
Aug-07-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy (GlobeNewswire)
08:30AM	Loading…
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +7.38%
Aug-05-25 08:30AM	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space (GlobeNewswire)
Aug-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.50%
08:30AM	Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas (PR Newswire)
Jul-31-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +134.40%
09:00AM	Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial (Benzinga)
07:30AM	Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease (PR Newswire)
05:31AM	Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON (GlobeNewswire)
Jul-08-25 07:30AM	Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones (PR Newswire) +8.93%
Jul-01-25 07:30AM	Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions (PR Newswire) +7.63%
Jun-06-25 09:37AM	Soligenix Highlights Dr. Ellen Kims Recent Q&A and the Promise of HyBryte in Ongoing Clinical Trials (GlobeNewswire)
May-09-25 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results (PR Newswire)
Apr-14-25 07:30AM	Positive Outcome in 75% of CTCL Patients Treated with HyBryte for 18 Weeks (PR Newswire) -9.89%
Mar-25-25 08:30AM	IBN Initiates Coverage of Soligenix Inc. (GlobeNewswire)
07:30AM	Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 Variants (PR Newswire)
07:30AM	Loading…
Mar-21-25 07:30AM	Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results (PR Newswire)
Mar-06-25 07:30AM	HyBryte Treatment Studies Presented at Two Medical Conferences in March (PR Newswire)
Feb-04-25 07:30AM	Soligenix to Present at BIO CEO & Investor Conference (PR Newswire)
Jan-16-25 07:30AM	Soligenix to Present at Upcoming Investor Conferences (PR Newswire)
Jan-14-25 07:30AM	HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma (PR Newswire) -15.97%
07:15AM	EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year (Benzinga)
Dec-17-24 10:24AM	Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial (Clinical Trials Arena)
07:35AM	Soligenix initiates confirmatory Phase 3 trial of HyBryte (TipRanks)
Dec-16-24 07:30AM	Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire)
07:15AM	EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer (Benzinga)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESSWIRE)
Dec-02-24 07:30AM	HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment (PR Newswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-19-24 07:30AM	Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma (PR Newswire)
Nov-15-24 07:30AM	Soligenix to Present at November 21st Virtual Investor Summit Microcap Event (ACCESSWIRE)
Nov-14-24 07:15AM	Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels (Benzinga)
07:15AM	Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behet's Disease (PR Newswire)
Nov-08-24 07:30AM	Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results (PR Newswire)
Oct-29-24 07:30AM	Soligenix Announces Participation at the Spartan Capital Investor Conference (NewMediaWire)
Oct-24-24 07:30AM	Soligenix, Inc. to Present at the 2024 ThinkEquity Conference (GlobeNewswire)
Oct-22-24 07:30AM	Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin (PR Newswire)
Oct-16-24 07:30AM	Soligenix Invited to Present at Upcoming Investor Conferences (PR Newswire)
Oct-07-24 07:30AM	HyBryte Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference (PR Newswire) +9.30%
Oct-03-24 07:30AM	Soligenix Announces Partnership with Sterling Pharma Solutions (PR Newswire) -18.89%
Sep-20-24 09:00AM	Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-16-24 07:30AM	Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 (PR Newswire)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
Sep-03-24 07:30AM	Soligenix Receives European Patent for Improved Production of Synthetic Hypericin (PR Newswire) +8.86%
Aug-16-24 09:00AM	Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +13.77%
Aug-09-24 07:30AM	Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results (PR Newswire)
Aug-01-24 09:00AM	Strong Clinical Momentum for Soligenix's HyBryte in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone (GlobeNewswire)
Jul-31-24 09:53AM	7 Top Stocks Under $10: July 2024 Edition (InvestorPlace)
Jul-15-24 10:16AM	PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte Lighting the Way Towards Commercial Success with Promising FLASH Study Results (GlobeNewswire) -7.67%
Jul-10-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jul-09-24 02:37PM	5 Investors Betting Big on Soligenix (SNGX) Stock (InvestorPlace) +271.00%
10:04AM	Why Is Soligenix (SNGX) Stock Up 296% Today? (InvestorPlace)
07:30AM	Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma (PR Newswire)
Jun-25-24 07:30AM	Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte Against Valchlor in the Treatment of Cutaneous T-Cell Lymphoma (PR Newswire) -21.60%
Jun-14-24 07:30AM	A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference (PR Newswire)
Jun-07-24 09:00AM	Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.92%
Jun-05-24 08:00AM	Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte Replication Trial (GlobeNewswire)
May-31-24 07:30AM	Soligenix Announces Reverse Stock Split (PR Newswire) -10.00%
May-29-24 07:30AM	Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting (PR Newswire)
May-24-24 07:30AM	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting (PR Newswire)
May-23-24 07:30AM	Soligenix Encourages Stockholders to Vote 'FOR' Reverse Stock Split (PR Newswire) -8.65%
May-21-24 12:35PM	PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon (GlobeNewswire)
07:30AM	SuVax and MarVax Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference (PR Newswire)
May-20-24 07:30AM	Soligenix Encourages Stockholders to Vote Prior to Annual Meeting (PR Newswire)
May-16-24 07:30AM	Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice (PR Newswire) +7.29%
May-13-24 10:54AM	SNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-10-24 07:30AM	Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Soligenix to Present at Upcoming Conferences (PR Newswire)
Apr-25-24 07:30AM	Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa (PR Newswire) +11.49%
Apr-18-24 08:30AM	Soligenix Announces Pricing of $4.75 Million Public Offering (PR Newswire) -14.65%
Apr-15-24 03:55PM	Why Is Penny Stock Soligenix Trading Higher On Monday? (Benzinga) +21.73%
11:18AM	Why Is Soligenix (SNGX) Stock Up 58% Today? (InvestorPlace)
07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection (PR Newswire)
Apr-11-24 07:30AM	FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection (PR Newswire) -16.05%
Apr-03-24 07:30AM	Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte With the European Medicines Agency (PR Newswire) -10.15%
Mar-15-24 01:53PM	SNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:30AM	Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results (PR Newswire)
Feb-08-24 07:30AM	Soligenix Announces Formation of Behet's Disease Medical Advisory Board (PR Newswire) +5.54%
Jan-26-24 09:00AM	Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jan-25-24 07:30AM	Soligenix to Present at The Microcap Conference (PR Newswire)
Jan-08-24 07:30AM	FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behet's Disease (PR Newswire) +16.68%
Jan-04-24 07:30AM	Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis (PR Newswire)
Jan-02-24 07:30AM	Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses (PR Newswire) +12.26%
Dec-01-23 07:30AM	'HyBryte Use in Early-Stage Cutaneous T-Cell Lymphoma' Published in Frontiers in Drug Discovery (PR Newswire) -25.53%
Nov-30-23 11:07AM	Why Is Soligenix (SNGX) Stock Up 285% Today? (InvestorPlace) +135.97%
07:30AM	Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behet's Disease (PR Newswire)

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHABER CHRISTOPHER J	CHAIRMAN, CEO AND PRESIDENT	Oct 02 '25	Buy	1.32	15,132	20,000	15,511	Oct 03 01:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNGX

Soligenix Inc

Upgrade your FINVIZ experience